GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » Revenue

PHAXIAM Therapeutics (XPAR:PHXM) Revenue : €0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics Revenue?

PHAXIAM Therapeutics's revenue for the three months ended in Sep. 2023 was €0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil. PHAXIAM Therapeutics's Revenue per Share for the three months ended in Sep. 2023 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


PHAXIAM Therapeutics Revenue Historical Data

The historical data trend for PHAXIAM Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics Revenue Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PHAXIAM Therapeutics's Revenue

For the Biotechnology subindustry, PHAXIAM Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PHAXIAM Therapeutics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's Revenue falls into.



PHAXIAM Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PHAXIAM Therapeutics  (XPAR:PHXM) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


PHAXIAM Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Traded in Other Exchanges
Address
60 Avenue Rockefeller, Lyon, FRA, 69008
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.